Grifols, S.A. (GRFS)
Extracts proteins from donated blood plasma to make medicines for treating diseases.
$8.04+0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-25.4%
The outlook
Grifols is trading near the lower end of its 52-week range, with analyst coverage leaning bullish and an average price target about 35% above current levels. The stock is positioned below its key moving averages, suggesting a mixed near-term technical picture. At a trailing P/E of 11.7, valuations appear relatively modest compared to the consensus upside target.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 2 analysts
Price trendMixed vs its moving averages
52-week range26% of the way from its 52-week low to high
Price targetAvg target +35% vs current price
Analyst price target
~12-month · 2 analysts$10.87average target+35.1% vs now
Now $8.04
Low $10.00High $11.73
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$5.47B
52-wk high
$11.14
52-wk low
$6.96
50-day avg
$7.52
200-day avg
$8.47
Trailing P/E
11.7